Top

07-11-2017 | Melanoma | Article

Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases

Journal: Journal of Translational Medicine

Authors: Maria A. Pizzichetta, Daniela Massi, Mario Mandalà, Paola Queirolo, Ignazio Stanganelli, Vincenzo De Giorgi, Giovanni Ghigliotti, Stefano Cavicchini, Pietro Quaglino, Maria T. Corradin, Pietro Rubegni, Mauro Alaibac, Stefano Astorino, Fabrizio Ayala, Serena Magi, Laura Mazzoni, Maria Ausilia Manganoni, Renato Talamini, Diego Serraino, Giuseppe Palmieri, on behalf of the Italian Melanoma Intergroup (IMI)

Publisher: BioMed Central

Abstract

Background

Nodular melanoma (NM) accounts for most thick melanomas and because of their frequent association with ulceration, fast growth rate and high mitotic rate, contribute substantially to melanoma-related mortality. In a multicentric series of 214 primary melanomas including 96 NM and 118 superficial spreading melanoma (SSM), histopathological features were examined with the aim to identify clinicopathological predictors of recurrence.

Methods

All consecutive cases of histopathologically diagnosed primary invasive SSM and NM during the period 2005–2010, were retrieved from the 12 participating Italian Melanoma Intergroup (IMI) centers. Each center provided clinico-pathological data such as gender, age at diagnosis, anatomical site, histopathological conventional parameters, date of excision and first melanoma recurrence.

Results

Results showed that NM subtype was significantly associated with Breslow thickness (BT) at multivariate analysis: [BT 1.01–2 mm (OR 7.22; 95% CI 2.73–19.05), BT 2.01–4 mm (OR 7.04; 95% CI 2.54–19.56), and BT > 4 mm (OR 51.78; 95% CI 5.65–474.86) (p < 0.0001)]. Furthermore, mitotic rate (MR) was significantly correlated with NM histotype: [(MR 3–5 mitoses/mm² (OR 2.62; 95% CI 1.01–6.83) and MR > 5 mitoses/mm² (OR 4.87; 95% CI 1.77–13.40) (p = 0.002)]. The risk of recurrence was not significantly associated with NM histotype while BT [BT 1.01–2.00 mm (HR 1.55; 95% CI 0.51–4.71), BT 2.01–4.00 mm (HR 2.42; 95% CI 0.89–6.54), BT > 4.00 mm. (HR 3.13; 95% CI 0.95–10.28) (p = 0.05)], mitotic rate [MR > 2 mitoses/mm² (HR 2.34; 95% CI, 1.11–4.97) (p = 0.03)] and the positivity of lymph node sentinel biopsy (SNLB) (HR 2.60; 95% CI 1.19–5.68) (p = 0.007) were significantly associated with an increased risk of recurrence at multivariate analysis.

Conclusions

We found that NM subtype was significantly associated with higher BT and MR but it was not a prognostic factor since it did not significantly correlate with melanoma recurrence rate. Conversely, increased BT and MR as well as SNLB positivity were significantly associated with a higher risk of melanoma recurrence.

Fuglede NB, Brinck-Claussen UO, Deltour I, Boesen EH, Dalton SO, Johansen C. Incidence of cutaneous malignant melanoma in Denmark, 1978–2007. Br J Dermatol. 2011;2:349–53.CrossRef

UICC-TNM classification of malignant tumours. Eight edition, edited by Brierlev JD, Gospodarowicz MK and Wittekind C, 2017.

Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142:1551–8.PubMed

Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–71.CrossRefPubMedPubMedCentral

Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer. 2002;102:34–8.CrossRefPubMed

Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas, in the United States: beware of the nodular subtype. Arch Dermatol. 2005;141:745–50.PubMed

Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978–2007. Arch Dermatol. 2012;148:30–6.CrossRefPubMed

Wisco OJ, Sober AJ. Prognostic factors for melanoma. Dermatol Clin. 2012;30:469–85.CrossRefPubMed

Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef

10.

Cox DR. Regression model and life-tables. J R Stat Soc B. 1972;34:178–220.

11.

Bergenmar M, Hansson J, Brandberg Y. Detection of nodular and superficial spreading melanoma with tumor thickness ≤ 2.00 mm—an interview study. Eur J Cancer Prev. 2002;11:49–55.CrossRefPubMed

12.

Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C, et al. Patterns of detection of superficial spreading and nodular-type melanoma: a multicenter Italian study. Dermatol Surg. 2004;30:1371–6.PubMed

13.

Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008;113:3341–8.CrossRefPubMedPubMedCentral

14.

Zalaudek I, Marghoob AA, Scope A, Leinweber B, Ferrara G, Hofmann-Wellenhof R, et al. Three roots of melanoma. Arch Dermatol. 2008;144:1375–8.PubMed

15.

Tas F, Erturk K. Tumour infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients. Cancer Invest. 2017;35:501–5.CrossRefPubMed

16.

Egger ME, Dunki-Jacobs EM, Callender GG, Quillo AR, Scoggins CR, Martin RCG II, et al. Outcomes and prognostic factors in nodular melanomas. Surgery. 2012;152:652–60.CrossRefPubMed

17.

Deshmane V, Kalloli M, Chikaraddi S, Keerthi BR, Krishnappa R, et al. Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (Dermatol Intern Med). 2014;59:241–6.CrossRef

18.

Matheson JAH, te Marvelde L, Mailer S, Speakman D, Spillane J, Henderson MA, et al. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Res. 2016. https://doi.org/10.1097/CMR.0000000000000302.

19.

Mandala’M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, et al. Mitotic rate correlates with sentinel lymph node status, and out come in cutaneous melanoma greater than 1 mm in thickness: a multi-institutional study of 1524 cases. J Am Acad Dermatol. 2017;76:264–73.CrossRef

20.

Faut M, Wevers KP, Van Ginkel RJ, Diercks GFH, Hoekstra HJ, Kruijff S, et al. Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients. Ann Surg Oncol. 2016. https://doi.org/10.1245/s10434-016-5566-8.

21.

O’Connel EP, O’Leary DP, Fogarty K, Khan ZJ, Redmond HP. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Res. 2016;26:66–70.CrossRef

22.

Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, Ming ME. Characteristics associated with early and late melanoma metastases. Cancer. 2010;116:415–23.CrossRefPubMed

23.

Tas F, Erturk K. Presence of histological regression as a prognostic factor in cutaneous melanoma patients. Melanoma Res. 2016. https://doi.org/10.1097/CMR.0000000000000277.

24.

Gualano MR, Osella A, Scaioli G, Marra E, Bert F, Faure E, Baduael ES, Balagna E, Quaglino P, Fierro MT, Siliquini R, Ribero S. Prognostic role of histologic regression in primary cutaneous melanoma: a systematic review and Meta-analysis. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15552.PubMed

25.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, Mc Carthy SW, Saw RP, Thompson JF. Tumour-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678–83. https://doi.org/10.1200/JCO.2011.37.8539.CrossRefPubMed